Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762588 | 0.93 | POLB (0.41) | POLBALDH1A1CA1CA2CA12 | |
| SCHEMBL11954378 | 0.85 | POLB (0.36) | POLBALDH1A1CA1CA2MAPT | |
| SCHEMBL12707735 | 0.82 | POLB (0.40) | POLBALDH1A1CA1CA2CA12 | |
| SCHEMBL18792722 | 0.80 | POLB (0.39) | POLBALDH1A1CA1CA2CA12 | |
| SCHEMBL1728200 | 0.79 | GRIA1 (0.37) | CA1CA2CA12CA7CA14 | |
| SCHEMBL12090531 | 0.79 | POLB (0.52) | POLBALDH1A1CA1CA2CA12 | |
| SCHEMBL12709869 | 0.79 | POLB (0.38) | POLBALDH1A1CA1CA2CA12 | |
| SCHEMBL14740061 | 0.76 | GRIA1 (0.52) | POLBALDH1A1CA1CA2CA12 | |
| SCHEMBL14739086 | 0.76 | GRIA1 (0.52) | POLBALDH1A1CA1CA2CA12 | |
| SCHEMBL14739265 | 0.76 | GRIA1 (0.52) | POLBALDH1A1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230270889-A1 | Fluorescently-Traceable Amino Acid Derivative And Preparation Methods And Use Thereof | Capital Medical University (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230227408-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AZORA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-20230027864-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220409536-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2022-12-29 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-20210154148-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-05-27 | — | — | US | disclosed |
| US-10857105-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MordernaTX, Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-7498440-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7488827-B2 | Muscle relaxants; respiratory system disorders; asthma;COPD; emphysema; bronchitis | GLAXO GROUP LIMITED (GB) | 2009-02-10 | — | — | US | disclosed |
| US-7488827-B2 | Muscle relaxants; respiratory system disorders; asthma;COPD; emphysema; bronchitis | GLAXO GROUP LIMITED (GB) | 2009-02-10 | — | — | US | disclosed |
| US-7449486-B2 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080182992-A1 | Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents | ARRAY BIOPHARMA, INC. | 2008-07-31 | — | — | US | disclosed |
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | disclosed |
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | POLB 3924/4885ALDH1A1 2948/4885CA1 393/4885 |
| US-20210154148-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | POLB 2763/4885ALDH1A1 4530/4885CA1 4349/4885 |
| US-20230227408-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AHR, ARNT, NR4A1 | POLB 2458/4885ALDH1A1 750/4885CA1 4880/4885 |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AHR, ARNT, NR4A1 | POLB 2458/4885ALDH1A1 750/4885CA1 4880/4885 |
| US-20080182992-A1 | Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents | KIF5B, KIF2C, KIFC1 | POLB 805/4885ALDH1A1 1820/4885CA1 2440/4885 |
| US-10857105-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | POLB 2763/4885ALDH1A1 4530/4885CA1 4349/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | POLB 220/4885ALDH1A1 2235/4885CA1 439/4885 |
| US-20230027864-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | LCP2, CD14, MYD88 | POLB 2067/4885ALDH1A1 4722/4885CA1 3996/4885 |
| US-20220409536-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | POLB 2763/4885ALDH1A1 4530/4885CA1 4349/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | POLB 3174/4885ALDH1A1 115/4885CA1 3810/4885 |
| US-20230270889-A1 | Fluorescently-Traceable Amino Acid Derivative And Preparation Methods And Use Thereof | SLC7A5, BCAT2, BCAT1 | POLB 3660/4885ALDH1A1 3525/4885CA1 4584/4885 |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | POLB 3924/4885ALDH1A1 2948/4885CA1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.